Fosun Pharma (600196.SH): Compound polyethylene glycol (3350) electrolyte powder has received registration approval.

According to the Zhizhong Finance APP, Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has recently received approval from the National Medical Products Administration for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Granules. The approved indications are (1) for the treatment of chronic constipation in children aged 1 to 11; (2) for the treatment of fecal impaction in children aged 5 to 11, i.e., severe constipation accompanied by the accumulation of fecal matter in the rectum and/or colon.